Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 17/20 | 0.52 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1126738 | 0.89 | FGFR3 (0.58) | FGFR3G6PDPDE4APDE4BPDE4C | |
| SCHEMBL3316051 | 0.89 | FGFR3 (0.51) | FGFR3G6PDPDE4APDE4BPDE4C | |
| Amitrole SCHEMBL3317173 | 0.87 | FGFR3 (0.51) | FGFR3G6PDPDE4APDE4BPDE4C | |
| SCHEMBL1126081 | 0.86 | FGFR3 (0.56) | FGFR3G6PDPDE4APDE4BPDE4C | |
| SCHEMBL1126323 | 0.85 | FGFR3 (0.57) | FGFR3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1126014 | 0.82 | FGFR3 (0.61) | FGFR3G6PDPDE4APDE4BPDE4C | |
| SCHEMBL3316982 | 0.82 | FGFR3 (0.58) | FGFR3G6PD | |
| SCHEMBL3317157 | 0.82 | FGFR3 (0.49) | FGFR3G6PDPDE4APDE4BPDE4C | |
| SCHEMBL1126501 | 0.81 | FGFR3 (0.68) | FGFR3PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3315645 | 0.81 | FGFR3 (0.51) | FGFR3G6PD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | NOVARTIS AG | 2010-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105667-A1 | Quinoxaline- and Quinoline-Carboxamide Derivatives | ABL1, NQO2, MAP4K5 | FGFR3 1515/4885G6PD 206/4885PDE4A 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.